Cresset Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Cresset Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,633	Closed	-$861K	–	1098
2021 Q1	$861K	Sell	5,633 -1,514	-21%	-$234K	0.01%	334
2020 Q4	$1.12M	Sell	7,147 -9,882	-58%	-$1.27M	0.02%	224
2020 Q3	$1.95M	Sell	17,029 -3,578	-17%	-$386K	0.04%	171
2020 Q2	$2.31M	Buy	+20,607	New	+$2.19M	0.05%	133
2019 Q2	–	Sell	-633	Closed	-$86K	–	1943
2019 Q1	$86K	Sell	633 -29	-4%	-$3.61K	﹤0.01%	607
2018 Q4	$64K	Buy	+662	New	+$78.3K	﹤0.01%	424

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Cresset Asset Management's ALXN Position: Q2 2021 in Review

Cresset Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 5,633 shares — an estimated $861K sold.

Cresset Asset Management first reported a position in ALXN in Q4 2018 and held it in 6 quarters. The position peaked at $2.31M in Q2 2020. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

Cresset Asset Management reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Cresset Asset Management sold 5,633 Alexion Pharmaceuticals shares in Q2 2021, an estimated $861K.
Cresset Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 6 quarters.
Cresset Asset Management's Alexion Pharmaceuticals position peaked at $2.31M in Q2 2020.
707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Cresset Asset Management's 13F filing for Q2 2021, filed 10 Aug 2021.